Vantictumab, formerly known as OMP18R5, represents an novel cloned body designed to specifically block osteopontin molecule 18R5. This therapy is currently evaluated by Amgen in potential uses in multiple bone https://mediajx.com/story27732920/vantictumab-the-deep-investigation-into-this-cloned-antibody